BTIG Research Forecasts Strong Price Appreciation for Evolus (NASDAQ:EOLS) Stock

Evolus (NASDAQ:EOLS) had its target price upped by equities researchers at BTIG Research from $13.00 to $15.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research‘s price target would indicate a potential upside of 100.80% from the company’s previous close.

EOLS has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research note on Tuesday, August 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Evolus presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Evolus Stock Performance

NASDAQ:EOLS opened at $7.47 on Thursday. The stock has a 50-day simple moving average of $7.89 and a two-hundred day simple moving average of $6.29. The firm has a market capitalization of $493.39 million, a PE ratio of -14.37 and a beta of 1.38. Evolus has a 52-week low of $3.86 and a 52-week high of $9.31.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares in the company, valued at approximately $4,516,311.68. The trade was a 17.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.00% of the company’s stock.

Institutional Trading of Evolus

A number of large investors have recently modified their holdings of EOLS. Nantahala Capital Management LLC acquired a new stake in shares of Evolus in the second quarter valued at $38,878,026. BlackRock Inc. acquired a new stake in Evolus in the 2nd quarter valued at about $33,595,000. Rice Hall James & Associates LLC purchased a new position in shares of Evolus in the 2nd quarter valued at about $8,952,000. Perceptive Advisors LLC purchased a new position in shares of Evolus in the 1st quarter valued at about $5,289,000. Finally, AWH Capital L.P. acquired a new position in shares of Evolus during the second quarter worth about $4,337,500. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.